Skip to content
ES
MARKETS / NASDAQ / AIRS
NASDAQ · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE

Airsculpt Technologies, Inc. AIRS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$151.8M
▼ 15.8% YoY
$-11.7M
$692,000
In brief

What this company does

It delivers its procedures through a nationwide footprint of 31 centers across 20 U.S. states and Canada, as of March 31, 2026. As of December 31, 2025, it employed approximately 330 full-time employees and approximately 33 part-time employees, and had contracts with approximately 90 surgeons. The Company was founded in 2012 and reorganized in 2018 as part of the acquisition of a majority stake in the company by Vesey Street Capital Partners, L.L.C., its private equity sponsor, prior to the IPO. AirSculpt Technologies, Inc. was incorporated in Delaware on June 30, 2021 and completed an IPO on October 28, 2021.

Written from the business description in AirSculpt Technologies, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 151.8M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 151.8 · Net income -11.7
80M160M2019202020212022202320242025
Compound annual growth
−3.5%
+19.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−8 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -7.6% · Net -7.7%
5%10%15%-5%2019202020212022202320242025
ROE
FY2025 · ROE -14.1%
5%10%-5%-10%-15%2019202020212022202320242025
Gross margin59.4%
Operating margin-7.6%
Net margin-7.7%
Return on assets-5.8%
EBITDAUSD 1.2M

Each USD of equity lost 14 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.7
8M16M-1M-2M2019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends 0.0 · Net buybacks —
8M16M202020212022202320242025
Dividends paid—
Net buybacks—
Share of profit-0.0%
Consecutive raises—

Total assetsUSD 187.3M
EquityUSD 87.7M
CashUSD 8.4M
Gross debtUSD 56.0M
Net debtUSD 47.6M
Current ratio0.55×

Net debt stands at 54% of equity.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.20.20.20.20.10.10.0
Operating income $B−0.0−0.00.0−0.00.00.00.0
EBITDA $B0.00.00.00.00.00.00.0
Income tax $B−0.00.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.00.00.0−0.0
Free cash flow $B0.0−0.00.00.00.00.00.0
EPS, diluted $−0.19−0.14−0.08−0.260.01··
Dividend / sh $···0.41···
Payout %−0−3−9−15800·
ROE %−14.1−10.0−5.5−19.012.6··
Shares out B0.060.060.060.060.060.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 64 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Offices & Clinics of Doctors of Medicine
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image